Marc A Rodger, Gregoire Le Gal, Philip Wells, Trevor Baglin, Drahomir Aujesky, Marc Righini, Gualtiero Palareti, Menno Huisman, Guy Meyer
Venous thromboembolism (VTE) is a potentially lethal clinical condition that is suspected in patients with common clinical complaints, in many and varied, clinical care settings. Once VTE is diagnosed, optimal therapeutic management (thrombolysis, IVC filters, type and duration of anticoagulants) and ideal therapeutic management settings (outpatient, critical care) are also controversial. Clinical prediction tools, including clinical decision rules and D-Dimer, have been developed, and some validated, to assist clinical decision making along the diagnostic and therapeutic management paths for VTE...
October 2014: Thrombosis Research
Scott Kaatz, An-Chen Fu, Azza AbuDagga, Joyce LaMori, Brahim K Bookhart, C V Damaraju, Hiangkiat Tan, Jeff Schein, Edith Nutescu
INTRODUCTION: This retrospective observational study examined whether anticoagulant treatment duration varies by risks of venous thromboembolism (VTE) recurrence and bleeding. MATERIALS AND METHODS: VTE patients naïve to anticoagulants were identified from the HealthCore Integrated Research Database between 06/01/2007 and 09/30/2011 and categorized into three groups: provoked, cancer-related, and unprovoked VTE. Treatment duration was from initiation to discontinuation of anticoagulation, based on a 60-day gap in prescription fill unless there was an international normalized ratio test every 42 days...
October 2014: Thrombosis Research
Paolo Prandoni, Sofia Barbar, Marta Milan, Elena Campello, Luca Spiezia, Chiara Piovella, Raffaele Pesavento
Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after a first episode is consistently around 30%. This risk is higher in patients with unprovoked than in those with (transient) provoked VTE, and among the latter in patients with medical than in those with surgical risk factors. Baseline parameters that have been found to be related to the risk of recurrent VTE are the proximal location of deep-vein thrombosis, obesity, old age, male sex and non-0 blood group, whereas the role of inherited thrombophilia is controversial...
June 2015: Thrombosis and Haemostasis
M Di Nisio, M Carrier, G H Lyman, A A Khorana
No abstract text is available yet for this article.
October 2014: Journal of Thrombosis and Haemostasis: JTH
Alessandro Squizzato, Walter Ageno
No abstract text is available yet for this article.
October 2014: Thrombosis and Haemostasis
N Sermsathanasawadi, P Suparatchatpun, T Pumpuang, K Hongku, K Chinsakchai, C Wongwanit, C Ruangsetakit, P Mutirangura
OBJECTIVES: The aim of this research was to compare the accuracy of the modified Wells, the Wells, the Kahn, the St. André, and the Constans score for the diagnosis of deep vein thrombosis of the lower limb in unselected population of outpatients and inpatients. METHOD: The pretest of probability score was employed in consecutive 500 outpatients and inpatients with suspicion of deep vein thrombosis. All patients were examined with compression ultrasonography. RESULTS: Deep vein thrombosis was confirmed in 26...
August 2015: Phlebology
S S Jameson, P N Baker, D J Deehan, A Port, M R Reed
The National Institute for Health and Clinical Excellence (NICE) has thus far relied on historical data and predominantly industry-sponsored trials to provide evidence for venous thromboembolic (VTE) prophylaxis in joint replacement patients. We argue that the NICE guidelines may be reliant on assumptions that are in need of revision. Following the publication of large scale, independent observational studies showing little difference between low-molecular-weight heparins and aspirin, and recent changes to the guidance provided by other international bodies, should NICE reconsider their recommendations? Cite this article: Bone Joint Res 2014;3:146-9...
May 2014: Bone & Joint Research
Francois Lamontagne, Lauralyn McIntyre, Peter Dodek, Diane Heels-Ansdell, Maureen Meade, Julia Pemberton, Yoanna Skrobik, Ian Seppelt, Nicholas E Vlahakis, John Muscedere, Graham Reece, Marlies Ostermann, Soundrie Padayachee, Jamal Alhashemi, Michael Walsh, Bradley Lewis, David Schiff, Alan Moody, Nicole Zytaruk, Martine Leblanc, Deborah J Cook
IMPORTANCE: Critically ill patients are at risk of venous thrombosis, and therefore guidelines recommend daily thromboprophylaxis. Deep vein thrombosis (DVT) commonly occurs in the lower extremities but can occur in other sites including the head and neck, trunk, and upper extremities. The risk of nonleg deep venous thromboses (NLDVTs), predisposing factors, and the association between NLDVTs and pulmonary embolism (PE) or death are unclear. OBJECTIVE: To describe the frequency, anatomical location, risk factors, management, and consequences of NLDVTs in a large cohort of medical-surgical critically ill adults...
May 2014: JAMA Internal Medicine
Dina Adams, Julie L Welch, Jeffrey A Kline
No abstract text is available yet for this article.
September 2014: Annals of Emergency Medicine
Silvia Bozzato, Alessandro Squizzato, Marco P Donadini, Luigina Guasti, Francesco Dentali, Walter Ageno
Acutely ill medical patients may be at increased risk of venous thromboembolism, both during hospitalization and after discharge. International guidelines recommend thromboprophylaxis for high-risk medical patients with low bleeding risk for a maximum of 14 days. There are two approaches to identify the high-risk patient: adhering to the inclusion criteria used in randomized clinical trials or using risk assessment models. With both approaches, about 40% of medical inpatients should result at increased risk of venous thrombosis...
December 2013: Expert Review of Cardiovascular Therapy
Harry R Büller, Hervé Décousus, Michael A Grosso, Michele Mercuri, Saskia Middeldorp, Martin H Prins, Gary E Raskob, Sebastian M Schellong, Lee Schwocho, Annelise Segers, Minggao Shi, Peter Verhamme, Phil Wells
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin...
October 10, 2013: New England Journal of Medicine
Andrew Tinsley, Steven Naymagon, Laura M Enomoto, Christopher S Hollenbeak, Bruce E Sands, Thomas A Ullman
BACKGROUND: Inflammatory bowel disease (IBD) patients are at increased risk for venous thromboembolism (VTE) compared to the general population. Practice guidelines recommend pharmacologic prophylaxis for IBD inpatients. AIM: Our aim was to determine the rates of pharmacologic VTE prophylaxis in ulcerative colitis (UC) inpatients at a tertiary referral center. We also assessed potential predictors of pharmacologic prophylaxis. METHODS: We conducted a retrospective cohort study of 377 UC patients between January 1st, 2007 and December 31st, 2011...
December 2013: Journal of Crohn's & Colitis
Matthew F G Greig, Stuart B Rochow, Michael A Crilly, Arduino A Mangoni
It has been claimed that there are over 25,000 preventable in-hospital deaths from venous thromboembolism annually in the UK. NICE and SIGN guidelines therefore recommend that all hospitalised patients are risk assessed for venous thromboembolism. The guidelines would recommend using pharmacological thromboprophylaxis for all patients aged 60 and above with reduced mobility and acute medical illness unless obvious contra-indications exist. Meta-analysis data regarding pharmacological thromboprophylaxis for medical patients demonstrate reductions in asymptomatic deep vein thrombosis (DVT) rather than fatal pulmonary embolism and mortality...
July 2013: Age and Ageing
N A Zakai, P W Callas, A B Repp, M Cushman
BACKGROUND: We sought to define the risk factors present at admission for venous thromboembolism (VTE) in medical inpatients and develop a risk model for clinical use. METHODS: Between January 2002 and June 2009, 299 cases of hospital-acquired VTE were frequency matched to 601 controls. Records were abstracted using a standard form for characteristics of the thrombosis, medical conditions and other risk factors. Weighted logistic regression and survey methods were used to develop a risk model for hospital-acquired VTE that was validated by bootstrapping...
April 2013: Journal of Thrombosis and Haemostasis: JTH
Dhruvil R Shah, Hui Wang, Richard J Bold, Xiaowei Yang, Steve R Martinez, Anthony D Yang, Vijay P Khatri, David H Wisner, Robert J Canter
BACKGROUND: Postoperative venous thromboembolism (VTE) is increasingly viewed as a quality of care metric, although risk-adjusted incident rates of postoperative VTE and VTE after hospital discharge (VTEDC) are not available. We sought to characterize the predictors of VTE and VTEDC to develop nomograms to estimate individual risk of VTE and VTEDC. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program database, we identified 471,867 patients who underwent inpatient abdominal or thoracic operations between 2005 and 2010...
July 2013: Journal of Surgical Research
Shumei Kato, Yuichi J Shimada, Patricia Friedmann, Glenn Kashan, Gregg Husk, Steven R Bergmann
OBJECTIVES: Venous thromboembolism (VTE) such as pulmonary embolism and deep venous thrombosis is the most common cause of preventable morbidity and mortality in hospitalized patients. Prophylaxis is recommended for medical patients older than 40 years with at least one risk factor. However, the currently recommended regimen prevents only about half of in-hospital VTE. The aim of this study was to identify the risk factors for development of VTE in medical inpatients who were already on recommended pharmacological prophylaxis...
June 2012: Coronary Artery Disease
Jean-Marie Januel, Guanmin Chen, Christiane Ruffieux, Hude Quan, James D Douketis, Mark A Crowther, Cyrille Colin, William A Ghali, Bernard Burnand
CONTEXT: Symptomatic venous thromboembolism (VTE) after total or partial knee arthroplasty (TPKA) and after total or partial hip arthroplasty (TPHA) are proposed patient safety indicators, but its incidence prior to discharge is not defined. OBJECTIVE: To establish a literature-based estimate of symptomatic VTE event rates prior to hospital discharge in patients undergoing TPHA or TPKA. DATA SOURCES: Search of MEDLINE, EMBASE, and the Cochrane Library (1996 to 2011), supplemented by relevant articles...
January 18, 2012: JAMA
Michael B Rothberg, Peter K Lindenauer, Maureen Lahti, Penelope S Pekow, Harry P Selker
BACKGROUND: The Joint Commission requires that all medical inpatients be assessed for venous thromboembolism (VTE) risk, but available risk stratification tools have never been validated. METHODS: We conducted a retrospective cohort study of patients age ≥18 years, admitted to 374 US hospitals in 2004-2005, with a primary diagnosis of pneumonia, heart failure, chronic obstructive pulmonary disease (COPD), stroke, and urinary tract infection, and length of stay ≥3 days...
April 2011: Journal of Hospital Medicine: An Official Publication of the Society of Hospital Medicine
Jean-Philippe Galanaud, Celine Genty, Marie-Antoinette Sevestre, Dominique Brisot, Michel Lausecker, Jean-Luc Gillet, Carole Rolland, Marc Righini, Georges Leftheriotis, Jean-Luc Bosson, Isabelle Quere
Superficial venous thrombosis (SVT) prognosis is debated and its management is highly variable. It was the objective of this study to assess predictive risk factors for concurrent deep-vein thrombosis (DVT) at presentation and for three-month adverse outcome. Using data from the prospective multicentre OPTIMEV study, we analysed SVT predictive factors associated with concurrent DVT and three-month adverse outcome. Out of 788 SVT included, 227 (28.8%) exhibited a concurrent DVT at presentation. Age >75years (odds ratio [OR]=2...
January 2011: Thrombosis and Haemostasis
Alexander T Cohen, Victor F Tapson, Jean-Francois Bergmann, Samuel Z Goldhaber, Ajay K Kakkar, Bruno Deslandes, Wei Huang, Maksim Zayaruzny, Leigh Emery, Frederick A Anderson
BACKGROUND: Information about the variation in the risk for venous thromboembolism (VTE) and in prophylaxis practices around the world is scarce. The ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess the prevalence of VTE risk in the acute hospital care setting, and to determine the proportion of at-risk patients who receive effective prophylaxis...
February 2, 2008: Lancet
2014-10-04 18:21:37
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.